A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat - Wikidata - wikimedia - TriplyDB

A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat

A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat

http://www.wikidata.org/entity/Q24606079

about

Pharmacological intervention of HIV-1 maturation Structural and functional insights into the HIV-1 maturation inhibitor binding pocket Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 Identification of potent maturation inhibitors against HIV-1 clade C Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis.HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).HIV-1 Capsid Inhibitors as Antiretroviral Agents New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C Human Immunodeficiency Virus Gag and protease: partners in resistance.Functional conservation of HIV-1 Gag: implications for rational drug design.Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets.Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.

P2860

Q26771739-9ABF2708-3A91-4BB0-ACD0-7CFB2E7FC1CD Q28485054-5AEA47F1-3850-4C84-B21B-534AC1792501 Q28554482-1CCBB023-57FC-46F2-8419-D372CC33A016 Q28828191-C9CE0F05-CD1C-462E-B04D-A7BAF76CBCEE Q28829072-71F3A616-8200-48FE-A92B-119E8D2AFFD3 Q34499377-B40CAFD1-D8F3-4FA8-95A4-068043F90B82 Q35761626-88896180-6A41-4DA2-A6B8-47BA4FB1699A Q35992805-0E191448-359C-42E0-B3F5-313EF6D946D7 Q36667054-002551E6-ABB8-4321-9B4B-AF5555C8AE28 Q36672006-697519EB-AC51-4FE7-9D0D-FFDEB6793878 Q36691642-1C95D7B3-2146-414B-9E04-2D2DD72527B5 Q37676344-CF6D6254-9A79-41D5-B5D2-BDE97B8D8E53 Q38032330-CA1C15B0-FE87-41D3-83A2-1B6008F259D5 Q41822002-D093ED9D-D98A-485E-9996-B105EC2C9EA3 Q41844750-A5EE2532-949C-4634-9576-6941333EA929 Q53688749-0EBFF82F-3B68-4FDA-8F1A-0EF26445BC3E Q53720583-71728687-498F-434E-AED1-2CD98E3D4AEC

P2860

A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat

http://www.wikidata.org/entity/Q24606079

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@ast

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@en

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@nl

type

label

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@ast

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@en

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@nl

prefLabel

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@ast

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@en

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@nl

P1433

Q24606079-B3949323-D66D-487D-9B5E-F5B08C3D7928

P1476

Q24606079-E9596D36-8AD7-4EC7-B09C-B0D950F1B8D9

P2093

Q24606079-0446D695-E426-46D8-9B43-115273F579F0

Q24606079-1E4E4C87-A5FD-4175-963E-B90C758B1AD2

Q24606079-5429C04B-762F-41E9-AEFC-AE8DDE3FA187

Q24606079-8D518611-C883-42CD-8B28-BF464FA99374

Q24606079-97803545-56E8-4074-8E70-2F10F874B60A

Q24606079-E381005C-43C7-4A68-B13A-80C00F1D2A6C

P2860

Q24606079-12242982-AECE-4F40-A203-594C53D6AB21

Q24606079-1746E7B9-62B7-4AEE-AAB1-3714D4842283

Q24606079-234F0FDD-6BB0-4AB6-8579-6D5D3BFBAA3F

Q24606079-2F875E84-2BE3-4F9F-9B20-691FB9B4A177

Q24606079-50CF02A7-28B1-4716-96F6-151565A64D3F

Q24606079-5945803A-DBA1-46A7-8A0E-C6C0415825D5

Q24606079-63502242-34F2-4B97-A018-4527F819C10F

Q24606079-6C42066B-4348-42E7-82D8-CB5B4C02829B

Q24606079-7EE311E7-CDA9-48D2-8B78-BE4D0570C0FC

Q24606079-82187F3D-D13E-4D90-84E9-B19F135B14CC

P304

Q24606079-0DA49A71-B053-46DD-987C-D94DD85935ED

P31

Q24606079-D7F341D7-13D1-495D-ADF3-432576811E9D

P3181

Q24606079-04A0FF0E-33CD-46BC-BDB7-97DD3066FD95

P356

Q24606079-0314B615-2125-4517-9334-51E34748324F

P407

Q24606079-4796189B-0C8C-4151-9D09-623132183E8F

P433

Q24606079-DB08D243-304D-4BBD-9495-B9F775CA3171

P478

Q24606079-06443E5E-1DD9-4AD3-95FD-0A31B908FE23

P50

Q24606079-19A07852-7A38-41D6-B806-CAF58D0B69AB

P577

Q24606079-6545C738-7D41-4DD5-ADB8-C96EEE3671CB

P5875

Q24606079-736FF893-0B6C-43DC-8627-1CC673E46EB0

P698

Q24606079-EDE2F5B0-8790-4831-8EA7-F201680DFA8D

P932

Q24606079-3DB89FAA-6B7C-4724-A9FD-86C83EF4280D

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

A single polymorphism in HIV-1 ...... maturation inhibitor bevirimat

@en

P2093

Carl T Wild

http://www.w3.org/2001/XMLSchema#string

Eric O Freed

http://www.w3.org/2001/XMLSchema#string

Feng Li

http://www.w3.org/2001/XMLSchema#string

Karl Salzwedel

http://www.w3.org/2001/XMLSchema#string

Suvobrata Chakravarty

http://www.w3.org/2001/XMLSchema#string

Wuxun Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid

Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination

A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly

Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone.

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat

Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

P304

3324-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1005618

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.01435-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51060383

http://www.w3.org/2001/XMLSchema#string

P698

21502630

http://www.w3.org/2001/XMLSchema#string

P932

3122462

http://www.w3.org/2001/XMLSchema#string